Bicycle Therapeutics plc. (9/6/22). "Press Release: Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference". Cambridge & Boston, MA.

	Organisation	Bicycle Therapeutics plc (Nasdaq: BCYC)
	Group	Bicycle Therapeutics (Group)
	Organisation 2	Morgan Stanley & Co. LLC
	Group	Morgan Stanley (Group)
	Product	Morgan Stanley Global Healthcare Conference 2022 New York
	Product 2	Bicycle Drug Conjugates®
	Index term	Bicycle Therapeutics–Morgan Stanley: investor conference, 202209 supply service Bicycle to participate in Morgan Stanley Global Healthcare Conference
	Person	Borah, David (Bicycle Therapeutics 202110 VP, Capital Markets + Investor Relations)
	Person 2	Sutton, Sarah (Argot Partners 202110 before WPP/Glover Park Group + Ten Bridge Communications)

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13th, 2022 at 10:00 a.m. ET.

A live webcast of the fireside chat will be accessible in the Investors and Media section of Bicycle’s Website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the fireside chat date.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

Investors:
David Borah, CFA
VP, Capital Markets & Investor Relations
david.borah@bicycletx.com
617-203-8300

Media:
Argot Partners
Sarah Sutton
bicycle@argotpartners.com
212-600-1902

Record changed: 2024-09-23